2023
Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US
Kc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang S, Silber A, Leapman M, Leeds I, Wheeler S, Spees L, Gross C, Lustberg M, Greenup R, Justice A, Oeffinger K, Dinan M. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US. JAMA Network Open 2023, 6: e2323115. PMID: 37436746, PMCID: PMC10339147, DOI: 10.1001/jamanetworkopen.2023.23115.Peer-Reviewed Original ResearchConceptsLong-term survivorsCancer-specific mortalityColorectal cancerCancer cohortReceptor statusInitial diagnosisGleason scoreProstate cancerBreast cancerLong-term adult survivorsMedian cancer-specific survivalEnd Results cancer registryProstate-specific antigen levelRectal cancer cohortCancer-specific survivalStage III diseaseYear of diagnosisProgesterone receptor statusEstrogen receptor statusProportion of deathsSurvival time ratioEarly-stage cancerNononcologic outcomesIndex cancerLocalized diseaseManaging Chronic Pain in Cancer Survivorship: Communication Challenges and Opportunities as Described by Cancer Survivors
O’Regan A, Fish L, Makarushka C, Somers T, Jones K, Merlin J, Dinan M, Oeffinger K, Check D. Managing Chronic Pain in Cancer Survivorship: Communication Challenges and Opportunities as Described by Cancer Survivors. American Journal Of Hospice And Palliative Medicine® 2023, 41: 78-86. PMID: 36927121, DOI: 10.1177/10499091231164634.Peer-Reviewed Original ResearchPain management experiencesCurative-intent treatmentChronic painCancer survivorsPain managementProvider-initiated communicationChronic pain managementHead/neckCancer survivors' experiencesDecision-making interventionSurvivorship careColorectal cancerClinical managementCancer survivorshipPainPain experienceStage ISurvivorsConvenience sampleSurvivors' experiencesTreatmentFunctional goalsCareThematic approachProviders
2020
Rapid rise in the cost of targeted cancer therapies for Medicare patients with solid tumors from 2006 to 2015
Wilson LE, Greiner MA, Altomare I, Rotter J, Dinan MA. Rapid rise in the cost of targeted cancer therapies for Medicare patients with solid tumors from 2006 to 2015. Journal Of Geriatric Oncology 2020, 12: 375-380. PMID: 33250425, DOI: 10.1016/j.jgo.2020.11.007.Peer-Reviewed Original ResearchConceptsProstate cancerCancer costsLung cancerBreast cancerProportion of patientsSystemic anticancer therapyPart D enrollmentNew malignanciesPatients 65Systemic therapyMedicare 5Colorectal cancerInvasive lungMedicare patientsCohort analysisMedicare populationMedicare beneficiariesPatientsSolid tumorsTherapyCancerAnticancer therapyCancer therapyFinancial burdenLung
2018
Nationwide utilization and costs of targeted anti-cancer drugs for elderly patients with solid tumors in the United States, 2004-2015.
Wilson L, Greiner M, Altomare I, Rotter J, Dinan M. Nationwide utilization and costs of targeted anti-cancer drugs for elderly patients with solid tumors in the United States, 2004-2015. Journal Of Clinical Oncology 2018, 36: 23-23. DOI: 10.1200/jco.2018.36.30_suppl.23.Peer-Reviewed Original ResearchTargeted anti-cancer drugsCancer spendingCancer patientsD patientsBC patientsAnti-cancer drugsColorectal cancer populationPatients age 65Breast cancer patientsLung cancer patientsMedicare spendingElderly lungsElderly patientsPatient ageCC patientsLC patientsMedicare 5Colorectal cancerInvasive lungPatient populationCancer populationMedicare patientsNationwide utilizationRetrospective analysisMean cost
2013
Oral contraceptive use for the primary prevention of ovarian cancer.
Havrilesky LJ, Gierisch JM, Moorman PG, Coeytaux RR, Urrutia RP, Lowery WJ, Dinan M, McBroom AJ, Wing L, Musty MD, Lallinger KR, Hasselblad V, Sanders GD, Myers ER. Oral contraceptive use for the primary prevention of ovarian cancer. Evidence Report Technology Assessment 2013, 1-514. PMID: 24423062, PMCID: PMC4781074.Peer-Reviewed Original ResearchConceptsOvarian cancer preventionOral contraceptivesVascular eventsOvarian cancerOC useOC usersPrimary preventionHarm/benefit ratioCervical cancerColorectal cancerCancer incidenceCancer preventionUse of OCsPersistent human papillomavirus (HPV) infectionCurrent OC usersBenefit ratioHuman papillomavirus infectionOral contraceptive useBreast cancer incidenceOvarian cancer incidenceLife expectancyOvarian cancer outcomeRisk of breastRandom-effects modelEnglish-language studies
2010
Changes in the Use and Costs of Diagnostic Imaging Among Medicare Beneficiaries With Cancer, 1999-2006
Dinan MA, Curtis LH, Hammill BG, Patz EF, Abernethy AP, Shea AM, Schulman KA. Changes in the Use and Costs of Diagnostic Imaging Among Medicare Beneficiaries With Cancer, 1999-2006. JAMA 2010, 303: 1625-1631. PMID: 20424253, DOI: 10.1001/jama.2010.460.Peer-Reviewed Original ResearchConceptsNon-Hodgkin lymphomaLung cancerMedicare beneficiariesBreast cancerCancer typesColorectal cancerProstate cancerImaging costsPositron emission tomography scanIncident breast cancerYear of diagnosisEmission tomography scanBone density studiesMean total costMagnetic resonance imagingPositron emission tomographyBone scanTreatment patternsIncident casesCancer careHalf of beneficiariesTomography scanUS CentersMean annual increaseResonance imaging